It has restricted expression in normal cells but is highly-expressed in various non-mucinous tumours of epithelial origin, including ovarian cancer, where increasing levels of tissue FRα are associated with tumour progression from early to advanced stages making it an attractive therapeutic target [385]. Here, FOLR1 is linked to neoplasm.